PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

66 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
Alle Publikationen dieser Seite in den Korb legen
41.
Hutter, G. et al.: Proteasome inhibition leads to dephosphorylation and downregulation of protein expression of members of the Akt/mTOR pathway in MCL. Leukemia 26, 2442-2444 (2012)
42.
Loder, S.* et al.: RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosis. Leukemia 26, 1020-1029 (2012)
43.
Mulaw, M.A. et al.: CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12. Leukemia 26, 1012-1019 (2012)
44.
Deshpande, A.J. et al.: The clathrin-binding domain of CALM and the OM-LZ domain of AF10 are sufficient to induce acute myeloid leukemia in mice. Leukemia 25, 1718-1727 (2011)
45.
Greif, P.A. et al.: Identification of recurring tumor-specific somatic mutations in acute myeloid leukemia by transcriptome sequencing. Leukemia 25, 821-827 (2011)
46.
Greif, P.A. et al.: Somatic mutations in acute promyelocytic leukemia (APL) identified by exome sequencing. Leukemia 25, 1519-1522 (2011)
47.
Herold, T.* et al.: An eight-gene expression signature for the prediction of survival and time to treatment in chronic lymphocytic leukemia. Leukemia 25, 1639-1645 (2011)
48.
Kakadia, P.M. et al.: A novel ABL1 fusion to the SH2 containing inositol phosphatase-1 (SHIP1) in acute lymphoblastic leukemia (ALL). Leukemia 25, 1645-1649 (2011)
49.
Konstandin, N.P. et al.: Genomic 5-hydroxymethylcytosine levels correlate with TET2 mutations and a distinct global gene expression pattern in secondary acute myeloid leukemia. Leukemia 25, 1649-1652 (2011)
50.
Pulikkan, J.A.* et al.: Elevated PIN1 expression by C/EBPα-p30 blocks C/EBPα-induced granulocytic differentiation through c-Jun in AML. Leukemia 24, 914-923 (2010)
51.
Thoene, S. et al.: The homeobox gene CDX2 is aberrantly expressed and associated with an inferior prognosis in patients with acute lymphoblastic leukemia. Leukemia 23, 649-655 (2009)
52.
Bararia, D. et al.: Proteomic identification of the MYST domain histone acetyltransferase TIP60 (HTATIP) as a co-activator of the myeloid transcription factor C/EBPalpha. Leukemia 22, 800-807 (2008)
53.
Klier, M. et al.: Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 22, 2097-2105 (2008)
54.
Schyschka, L.* et al.: Spongistatin 1: A new chemosensitizing marine compound that degrades XIAP. Leukemia 22, 1737-1745 (2008)
55.
Kohl, T.M. et al.: BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts. Leukemia 21, 1763-1772 (2007)
56.
Schmetzer, H.M.* ; Kremser, A.* ; Loibl, J.* ; Kroell, T.* & Kolb, H.-J.: Quantification of ex vivo generated dendritic cells (DC) and leukemia-derived DC contributes to estimate the quality of DC, to detect optimal DC-generating methods or to optimize DC-mediated T-cell-activation-procedures ex vivo or in viv. Leukemia 21, 1338-1341 (2007)
57.
Schneider, F.* et al.: AML1-ETO meets JAK2: Clinical evidence for the two hit model of leukemogenesis from a myeloproliferative syndrome progressing to acute myeloid leukemia. Leukemia 21, 2199-2201 (2007)
58.
Weigert, O. et al.: Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 21, 524-528 (2007)
59.
Kremer, M.* et al.: The JAK2 V617F mutation occurs frequently in myelodysplastic/myeloproliferative diseases, but is absent in true myelodysplastic syndromes with fibrosis. Leukemia 20, 1315-1316 (2006)
60.
Feuring-Buske, M. et al.: Improved engraftment of human acutre myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NHOD/SCID transgenic for human growth factors. Leukemia 17, 760-763 (2003)